Angebote zu "Disease" (16 Treffer)

Kategorien

Shops

Pathogenesis and Clinical Practice in Gastroent...
139,05 € *
ggf. zzgl. Versand

List of principal contributors.- List of chairpersons.- Preface.- Section I: Dysphagia and reflux.- Section II: Helicobacter pylori, NSAID, gastric cancer.- Section III: Inflammatory bowel disease section.- Section IV: Lower gastrointestinal tract (coeliac disease, infection and malignancy).- Section V: clinical challenges in liver diseases.- Section VI: viral hepatitis.- Section VII: Metabolic and autoimmune liver injury.- Section VIII: Complications of cirrhosis.- Index.

Anbieter: Thalia AT
Stand: 06.12.2019
Zum Angebot
Pathogenesis and Clinical Practice in Gastroent...
240,90 CHF *
ggf. zzgl. Versand

List of principal contributors.- List of chairpersons.- Preface.- Section I: Dysphagia and reflux.- Section II: Helicobacter pylori, NSAID, gastric cancer.- Section III: Inflammatory bowel disease section.- Section IV: Lower gastrointestinal tract (coeliac disease, infection and malignancy).- Section V: clinical challenges in liver diseases.- Section VI: viral hepatitis.- Section VII: Metabolic and autoimmune liver injury.- Section VIII: Complications of cirrhosis.- Index.

Anbieter: Orell Fuessli CH
Stand: 06.12.2019
Zum Angebot
Probiotics
136,99 € *
ggf. zzgl. Versand

Probiotic has been used for centuries especially in fermented dairy products since Metchnikoff associated the intake of fermented milk with prolonged life. Probiotics confer many health benefits to humans, animals, and plants when administered in proper amounts. These benefits include the prevention of gastrointestinal infections and antibiotic-associated diarrhea, the reduction of serum cholesterol and allergenic and atopic complaints, and the protection of the immune system. Furthermore, the proper usage of probiotics could suppress Helicobacter pylori infection and Crohn's disease, improve inflammatory bowel disease, and prevent cancer. In this book, we present specialists with experience in the field of probiotics exploring their current knowledge and their future prospects.

Anbieter: Thalia AT
Stand: 06.12.2019
Zum Angebot
Bacterial flora in Crohn's disease tissues
69,99 € *
ggf. zzgl. Versand

Crohn's disease is an idiopathic, chronic, segmental and transmural inflammatory bowel disease. Three models implying a role for bacteria have been proposed: infection by a single, hitherto unknown pathogen; an unbalanced composition of the bowel flora; and an abnormally increased passage of bacteria through the bowel wall. We tested these hypotheses by an experimental approach combining morphology and molecular bacteriology. The test protocol consisted of microdissection of Crohn's lesions from histological slides, DNA isolation, purification and sequencing of bacterial DNA, and identification of bacteria based on these sequences. Legionellaceae were specific for Crohn. Ulcers in Crohn's disease were also enriched in Enterobacteriaceae. The bowel wall in Crohn's disease further contained larger numbers of bacteria than in controls. Overall, it is not yet possible to exclude the existence of a unique pathogen, such as in Helicobacter pylori-induced gastritis. Full-blown Crohn's disease is however clearly associated with important disturbances of the normal composition and spatial distribution of the intestinal flora.

Anbieter: Thalia AT
Stand: 06.12.2019
Zum Angebot
Proton Pump Inhibitors
175,99 € *
ggf. zzgl. Versand

This monograph contains a description of the discovery and development of a antisecretory therapy in the treatment of acid-related diseases: omeprazole, the first proton pump inhibitor. Overviews compare this and other proton pump inhibitors and discuss their pharmacology, including the mechanism of action, the effect on Helicobacter pylori infection, and the consequences of profound inhibition of gastric acid secretion. The pharmaceutic delivery system is described since it constitutes a special problem with this class of drugs. The clinical experience with proton pump inhibitors in acid-related diseases is reviewed with focus on gastro-esophageal reflux disease and peptic ulcer diseases including Helicobacter pylori and NSAID-induced ulcerations and Zollinger-Ellison syndrome. Finally, an overview is presented on the socio-economic impact of proton pump inhibitors in acid-related diseases emphasizing the important aspect of quality of life. The monograph is aimed at a broad readership with an interest in the development problems of this, at present, most commercially successful drug; the pharmacology of a 'tailor-made' drug for a specific target; the therapeutic strategies in acid-related diseases; and the dramatic changes in the long-term outcome results of the treatment of peptic ulcer diseases where most patients now can be cured from the disease after only one week of drug therapy.

Anbieter: Thalia AT
Stand: 06.12.2019
Zum Angebot
Proton Pump Inhibitors
124,99 € *
ggf. zzgl. Versand

This monograph contains a description of the discovery and development of a antisecretory therapy in the treatment of acid-related diseases: omeprazole, the first proton pump inhibitor. Overviews compare this and other proton pump inhibitors and discuss their pharmacology, including the mechanism of action, the effect on Helicobacter pylori infection, and the consequences of profound inhibition of gastric acid secretion. The pharmaceutic delivery system is described since it constitutes a special problem with this class of drugs. The clinical experience with proton pump inhibitors in acid-related diseases is reviewed with focus on gastro-esophageal reflux disease and peptic ulcer diseases including Helicobacter pylori and NSAID-induced ulcerations and Zollinger-Ellison syndrome. Finally, an overview is presented on the socio-economic impact of proton pump inhibitors in acid-related diseases emphasizing the important aspect of quality of life. The monograph is aimed at a broad readership with an interest in the development problems of this, at present, most commercially successful drug; the pharmacology of a 'tailor-made' drug for a specific target; the therapeutic strategies in acid-related diseases; and the dramatic changes in the long-term outcome results of the treatment of peptic ulcer diseases where most patients now can be cured from the disease after only one week of drug therapy.

Anbieter: Thalia AT
Stand: 06.12.2019
Zum Angebot
Molecular Features Distinguishing Gastric Cance...
118,99 € *
ggf. zzgl. Versand

Gastric cancer is a leading cause of cancer deaths, but analysis of its molecular and clinical characteristics has been complicated by histological and aetiological heterogeneity. Stomach cancers are 90% adenocarcinoma; lymphoma, carcinoid, and stromal tumours may occur. Adenocarcinoma can be subdivided into histological Lauren and the World Health Organization (WHO) classifications, but this information has not led to the development of histologic subtype-specific treatment options. One way to potentially improve treatment for gastric cancers is to better understand the pathogenesis of this disease, the contribution of Helicobacter pylori infection, and host immune response to lead to the development of integrated histological and molecular classification schemes for gastric cancer. The hope is that these studies may facilitate the development of clinical trials to explore therapies in defined sets of patients, ultimately improving survival from this deadly disease.

Anbieter: Thalia AT
Stand: 06.12.2019
Zum Angebot
Gastric & oesophageal adenocarcinoma
83,99 € *
ggf. zzgl. Versand

One in every eight cancers in the world develops in the oesophagus or stomach. While the incidence of gastric adenocarcinoma and oesophageal squamous cell carcinoma have declined in recent decades, oesophageal adenocarcinoma has increased more than any other cancer. Infection with Helicobacter pylori, dietary salt and smoking are the main risk factors for gastric and oesophageal cancer. Gastro-oesophageal reflux disease (GORD), Barrett's oesophagus and obesity are risk factors for oesophageal adenocarcinoma. Adenocarcinomas of the oesophago-gastric junction and cardia include two distinct types, one resembling gastric cancer caused by H.pylori infection, the other, associated with GORD, resembling Barrett's adenocarcinoma. Gender is also a major intrinsic factor, with upper gastrointestinal cancer much commoner in men. The current work examines this male predominance at the population level and with reference to Lauren histological type, showing that only intestinal-type but not diffuse type upper GI cancers occur more frequently in men.

Anbieter: Thalia AT
Stand: 06.12.2019
Zum Angebot
Cytokines in the Genesis and Treatment of Cancer
272,51 € *
ggf. zzgl. Versand

Cytokines in the Genesis and Treatment of Cancer provides a comprehensive picture of the dual role of host responses in promoting and inhibiting tumor progression. This volume represents an important investigation into the emerging intersection of cancer biology and cancer immunology. Divided into four sections, the volume's first three parts focus on cytokines in the genesis of cancer. The final section describes the notable progress - both in animal models and humans - in demonstrating the use of cytokine or anticytokine therapies for the prevention and treatment of cancer. Cytokines in the Genesis and Treatment of Cancer brings together an impressive array of internationally distinguished investigators who are devoted to the study of cytokines and cancer. Together, they produce an insightful, comprehensive discussion of cytokines and cancer that will serve as the perfect reference for all those working in the field. TOC:Overview and Introduction to Cancer and Inflammation.- Helicobacter Pylori.- HTLV-1.- Herpes Viruses.- TNF.- TGF-ß.- Interleukin 1 (IL-1) Family of Cytokines.- IL-4/13.- IL-6 and Castleman's disease.- Interleukin 10 (IL-10) Family of Cytokines.- Cytokines in Multiple Myeloma: Therapeutic Implications.- Murine Cytokine Models and the Genesis of Cancer.- Experimental Models of Cytokines and Cancer Prevention.- Cytokines in the Tumor Stroma.- Cytokines and Angiogenesis in Tumors.- Chemokines and Receptor Expression in Tumor Progression.- The Biology of Cancer Cachexia: Role of TNF±.- IL-2.- IL-12.- The Type I Interferon Family.- Combination Cytokine Therapy.- Novel Strategies for Targeting Cytokine Administration.- Cytokines and Cancer Vaccines.- Anti-cytokine Therapy.- Cytokines in the Supportive Care of Cancer.

Anbieter: Thalia AT
Stand: 06.12.2019
Zum Angebot